Coriolis secures investment from KKR to support next steps in growth and to expand global footprint.

Miller is an accomplished leader in cell and gene therapy drug development.

Offers enhanced stability and moisture protection for sensitive formulations, and a range of low water activity (Aw) excipients.

New plant will become the heart of the production operation with plans to introduce AI as standard on all inspection machines.

Drop in COVID-19 product sales spurs multi-year cost realignment program involving undisclosed layoffs in an effort to save $3.5 billion through 2024.

Presents products across nasal, pulmonary, eye care, injectables and dermal drug delivery, and digital health.

Aims to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24, and VAX-31.

Ocedurenone is currently being evaluated in a phase 3 trial in uncontrolled hypertension with potential in cardiovascular and kidney disease.

Successful completion supports expansion of its ongoing clinical trial in relapsed/refractory AL Amyloidosis.

New identity emphasizes broad experience in classical small-molecule chemical development and contract synthesis.

Move designed to scale the company's AI-driven compliance cloud platform globally.

Regulatory guidelines make testing for pediatric indications a necessary step in oncology R&D.

Thierry succeeds Mark Egerton who is retiring after 18 as CEO.

The U.S. remained the top overall ranked nation, with India continuing to make year-on-year growth.

BioNTech to pay $70 million upfront and additional development, regulatory and commercial milestones, with a potential value of more than $1 billion.

Adds further scientific resources and expertise to address complex process chemistry challenges.

Expansion of filling capacity will enhances integrated offering for manufacturing ADCs drug substance and drug product.

Aims to enhance existing infrastructure in four areas covering both pharmaceutical and cosmetic products.

Can now offer more plasmid material in high-quality and GMP grades and expand the services it offers for mRNA supply.

Will utilize Cryoport’s cryogenic logistics solutions and ISO-certified risk mitigation process for the delivery of patients’ reproductive materials.